MedPath

Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)

Not Applicable
Completed
Conditions
Psychotic Episode
Schizophrenia and Disorders With Psychotic Features
Interventions
Behavioral: Psychoeducational multicomponent intervention
Behavioral: SocialMIND
Behavioral: Psychosocial treatment
Drug: Psychotropic treatment
Registration Number
NCT03309475
Lead Sponsor
Instituto de Investigación Hospital Universitario La Paz
Brief Summary

The current investigation aims to compare two group intervention in patients with a first episode of psychosis, that is, people who have suffered their first psychotic episode within 5 years prior to their inclusion in the study. The experimental arm is a mindfulness-based social cognition training (SocialMind) designed by professionals with both formal training and clinical experience in the field of mindfulness and third generation cognitive-behavioral therapies. The active comparator arm is a psychoeducation program specifically designed for individuals with recent onset psychosis by members of the team with great experience in delivering such interventions. The main outcome is social functioning, as measured by the Personal and Social Performance Scale (PSP), an instrument developed for psychotic patients. The main hypothesis is that the improvement in social functioning will be larger among the participants on the experimental arm, because there is enough evidence suggesting that deficits in social cognition are present even in the first stages of psychotic syndrome and related to social functioning and general disability. Moreover, mindfulness-based interventions have proven themselves effective in other severe mental disorders.

Detailed Description

Social functioning is impaired among many patients with a first episode of psychosis, who also show a lower ability to recognize, understand and benefit from social stimuli (i.e., deficits in social cognition) than their pairs. Both deficits underlie the general functional impairment found across non-affective psychotic syndromes. Since currently available pharmacological strategies have not proven themselves effective in addressing this matter, new psychotherapeutic approaches should be developed. Investigators' main hypothesis is that a mindfulness-based social cognition group training (SocialMind) will improve social and general functioning, and that this improvement will be higher in the SocialMind than in the psychoeducation group. Given the association between oxidative stress and cognitive functioning, a relationship between oxidative stress biomarkers and intervention-related variables is also expected.

A research team with more than ten mental health professionals and many collaborators will carry and oversee the assessment sessions. A Pharmacology Department will analyse the biological samples. Regulated-trained, well-experienced clinicians will design and administer both interventions. The whole team will take part in the process of scientific publication and results dissemination.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
59
Inclusion Criteria
  • 18-45 years old
  • First hospitalization, first visit to mental health services with positive symptoms, onset of antipsychotic treatment, or first appearance of positive symptoms confirmed by an informant within the period of five years prior to the enrolment in the study;
  • Informed consent given
Exclusion Criteria
  • Clinical Global Impression (CGI) higher than 5 ("markedly ill")
  • Other Axis I diagnoses, except for substance use if psychotic symptoms remain at least 14 days after negative urine test.
  • Intellectual disability plus impaired global functioning prior to disorder onset
  • Generalized development disorder
  • Pregnancy
  • Attendance to either mindfulness programs or structured psychoeducational interventions at the time of the enrolment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Psychoeducational Multicomponent InterventionPsychosocial treatmentThe active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and a psychoeducational multicomponent intervention for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.
Psychoeducational Multicomponent InterventionPsychoeducational multicomponent interventionThe active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and a psychoeducational multicomponent intervention for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.
SocialMINDSocialMINDThe experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
SocialMINDPsychosocial treatmentThe experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
SocialMINDPsychotropic treatmentThe experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
Psychoeducational Multicomponent InterventionPsychotropic treatmentThe active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and a psychoeducational multicomponent intervention for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.
Primary Outcome Measures
NameTimeMethod
Change in social functioning8, 16, 36 and 48 weeks

Personal and Social Performance Scale (PSP) measures patient's functioning on different social areas, such as self-care, relationships, social activities and aggressive behavior.

Secondary Outcome Measures
NameTimeMethod
Change in clinical global impression8, 16, 36 and 48 weeks

Clinical Global Impression Scale for Schizophrenia (CGI-SCH) measures patients' clinical state and clinical change over time

Change in quality of life8, 16, 36 and 48 weeks

WHOQOL-BREF measures patient's quality of life according to World Health Organization parameters.

Change in social cognition8, 16, 36 and 48 weeks

Hinting task, Reading the Mind in the Eyes Test (RMET), Emotion Recognition task (ER-40) and Ambiguous Intentions and Attribution Questionnaire (AIHQ) measure main domains of social cognition.

Change in depressive symptoms8, 16, 36 and 48 weeks

Calgary Depression Scale for Schizophrenia (CDSS) measures depressive symptoms in psychotic patients through a personal interview

Change in mindful attention and awareness8, 16, 36 and 48 weeks

Mindfulness Attention Awareness Scale (MAAS) measures processes thought to be related to clinical outcomes in mindfulness-based interventions.

Change in global functioning8, 16, 36 and 48 weeks

Global Assessment of Functioning Scale (GAF) measures patient's general functioning using a single 0-100 scale.

Change in reflective functioning8, 16, 36 and 48 weeks

Reflective Functioning Questionnaire (RFQ-8) measures mentalization ability through a set of 8 questions

Change in oxidative stress and anti-inflammatory response8 and 48 weeks

Total antioxidant status, enzymatic activity and cytokines

Change in emotional intelligence8, 16, 36 and 48 weeks

Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT v2.0) measures emotional intelligence through a set of questions referred to different situations.

Change in psychotic symptoms8, 16, 36 and 48 weeks

Positive and Negative Symptoms Scale for Schizophrenia (PANSS) measures psychotic syndrome through a detailed clinical interview.

Change in anxiety symptoms8, 16, 36 and 48 weeks

Beck Anxiety Inventory (BAI) measures clinical anxiety through 21 items.

Change in neurocognition8, 16, 36 and 48 weeks

Four tasks of the Matrics Consensus Cognitive Battery (MCCB) measure different domains of neurocognition (symbol coding, letter number span, spatial span and CPT-IP)

Change in cognitive insight8, 16, 36 and 48 weeks

Beck Cognitive Insight Scale (BCIS) explores self-reflection and self-certainty, as parts of the cognitive insight construct

Trial Locations

Locations (1)

La Paz University Hospital

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath